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ABSTRACT 
Human α-glucosidase is an enzyme involved in the catalytic cleavage of the glucoside bond and 
involved in numerous functionalities of the organism, as well as in the insurgence of diabetes mellitus 2 
and obesity. Thus, developing chemicals that inhibit this enzyme is a promising approach for the 
treatment of several pathologies. Small peptides such as di- and tri-peptides may be in natural organism 
as well as in the GI tract in high concentration, coming from the digestive process of meat, wheat and 
milk proteins. In this work, we reported the first tentative hierarchical structure-based virtual screening 
of peptides for human α-glucosidase. The goal of this work is to discover novel and diverse lead 
compounds that my act as inhibitors of α-glucosidase such as small peptides by performing a computer 
aided virtual screening and to find novel scaffolds for further development. Thus, in order to select 
novel candidates with original structure we performed molecular dynamics (MD) simulations among 
the 12 top-ranked peptides taking as comparison the MD simulations performed on crystallographic 
inhibitor acarbose. The compounds with the lower RMSD variability during the MD, were reserved for 
in vitro biological assay. The selected 4 promising structures were prepared on solid phase peptide 
synthesis and used for the inhibitory assay, among them compound 2 showed good inhibitory activity, 
which validated our method as an original strategy to discover novel peptide inhibitors.  Moreover, 
pharmacokinetic profile predictions of these 4 peptides were also carried out with binary QSAR models 
using MetaCore/MetaDrug applications. 
KEYWORS: α-glucosidase, inhibitors, virtual screening, drug design, peptides, binary QSAR models, 
MD simulations, MetaCore/MetaDrug   
1. Introduction 
Glucosidases are enzymes abundant in the gastrointestinal (GI) tract, where they catalyze the final step 
of the carbohydrates digestion. This enzyme has drawn a great interest in the scientific community 
since the inhibition of the glucose absorption could be used to control the blood glucose level and for 
hypocaloric dietary regimen. Thus, an inhibitor of α-glucosidase may be used as therapeutic agent in the 
treatment of diabetes and obesity. However, due to its role in the metabolism of carbohydrates it has 
also been speculated to be useful in the management of other diseases in which the cell metabolism has 
a critical role, such as cancer, viral infection, hepatitis (Rutten et al., 2006). Dietary patterns and body 
exercises are in the line for treatment of incipient type 2 diabetes mellitus (DM-T2) also defined as pre-
diabetes. If this approach alone failed to lower the glucose concentration in the bloodstream, a 
medicinal approach should be recommended (Rutten et al., 2006).  
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Actually, six different types of antihyperglycemics are available on market: biguanides, sulphonylurea, 
glinidines, thiazolidinediones, dipeptidyl peptidase IV inhibitors and α-glucosidase inhibitors (Nathan, 
2007). -glucosidase inhibitors (AGIs) are reversible ligands, non specific through different maltase, 
and exert their effect by delaying the digestion of complex sugars in the gut, therefore, also the 
absorption is affected (L.K. Campbell, White and R.K. Campbell, 1996). AGIs might be an early 
treatment of patients with DM-T2, indeed due to their mechanism of action, acting specifically on 
postprandial glucose level, which is also a risk factor for cardiovascular events (Ceriello, 2005). 
Acarbose is the most widely prescribed AGI which is commercialized for the treatment of DM-T2, 
although it possesses several side effects, such as cephalea, sleeplessness, nausea, intestinal gas, and 
diarrhea (Van de Laar et al., 2005) (Figure 1). Among the natural products several polyphenols have α-
glucosidase inhibitory effects, in fact there is a growing market of nutraceuticals for dismetabolic 
diseases. A great effort has been done to find novel and safe inhibitors of α-glucosidase, especially 
among the herbal extracts, without serious drawbacks. This area is particularly prone to be involved in 
the development of functional foods and nutraceuticals or to develop novel lead compounds. Several 
microorganisms, including e.g.  Streptomyces sp. (Do and Joo, 1989), Bacillus sp. (H.S. Kim et al., 2011), 
Nelumbo n. (One, Hattori, Fukaya, Imai, Ohizumi, 2006), Grateloupia e. (K.Y. Kim, Nam, Kurihara, S.M. 
Kim, 2008), Ganoderma l. (S.D. Kim and H.J. Nho, 2004), and Pine bark (Y.M. Kim and H.J. Nho, 
2004) have been studied to produce AGIs. Recently, some peptides derived from Aspergillus o. N159-1 
(Kang, Yi, Soo, 2013) have been studied as inhibitors of α-glucosidase, indeed several peptides able to 
modulate the activity of α-glucosidase, have been found in a series of proteins from silkworm and 
phage peptides (Watanabe et al., 2013). Although these peptides are generally less potent than synthetic 
drugs they have a strong potentiality as active components for food fortification and as diet integrators. 
In this paper, we have identified a novel class of α-glucosidase peptides inhibitors by performing a 
computer aided drug-design protocol. Our experiments involved the building of a general purpose 
virtual peptide library containing around 10000 peptides (after preparation). In a further step this 
peptide library was screened by docking simulations, the hits were rescored by MM/GBSA and 
molecular dynamics (MD) simulations. The selected peptides were synthesized and tested on α-
glucosidase and the obtained results have been used to validate our approach. 
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Figure 1. AGI inhibitors: a) Acarbose; b) Miglitol; c) Voglibose.  
 
2. Materials and Methods 
2.1. Peptide Library Generation 
The peptide library has been built in house, by a python program which generates all possible 
combinations of strings containing three letters among the 20 one-letter code of the amino acids. By 
this way, the program generated 203 novel combinations of tripeptides without protonation states, 
which became around 10000 after ligand preparation being included also alternative protonation states 
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for some residues, e.g. for Histidines. These obtained strings database was converted in 3D chemical 
structures using Maestro molecular modeling suit (Schrödinger Release 2017-4: Maestro, Schrödinger, 
LLC, New York, NY, 2017). Then the peptide library needs to be prepared and manually amidated at 
the C-terminus.  
2.2. Protein Preparation 
The crystal structure of α-glucosidase (PDB ID, 3TOP) was obtained from the RCSB database (Shen, 
Qin, Ren, 2011; Joint Center for Structural Genomics, Crystal structure of Alpha-glucosidase (TM0752) 
from Thermotoga maritima at 2.50 A resolution RCSBPSP, (2004) 1-14). This structure needs to be 
prepared by protein preparation wizard (Sastry, Adzhigirey, Day, Annabhimoju and Sherman, 2013) 
tool embedded in Maestro molecular modeling suite. The PropKa program was used to locate 
protonation states at the physiological pH of 7.4 (Olsson, Søndergaard, Rostkowski and Jensen, 2011). 
Hydrogen atoms were added and minimized. In the raw pdb file, other molecules also present in the 
crystallization medium, these molecules have been removed. 
2.3. Glide Docking of the co-crystallized ligand docking 
In an early stage, we tested the suitability of Glide extra precision (XP) protocol to predict the ligand 
position of the reference compound (Friesner et al., 2006). Co-crystallized inhibitor acarbose was 
prepared by the LigPrep module, and then it was docked to the active sites of α-glucosidase by 
Glide/XP protocol. The binding cavity was assigned as an outer box of size 25x 25 x25 Å, determined 
by the position of the crystallographic ligand. The RMSD value for acarbose was calculated by SID 
(simulation interface) and compared crystallized acarbose after XP docking and was found as less than 
1.3 Å (Figure 2). 
 
 
Figure 2. Acarbose crystallographic ligand superimposed to Acarbose pose obtained after Glide docking. 
2.4. Peptide Library Docking  
Docking experiments were performed by Glide (Friesner et al., 2006). The grid to set up the docking 
was created with standard parameters optimized for peptide docking. The grid box coordinates were 
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centered at the crystallographic ligand and a size of 25.0 Å of each side was assigned. The peptide 
library was prepared by LigPrep tool (Sastry et al., 2013), the molecules ionized at a pH of 7.4 by Epik. 
The number of peptide ligands, including tautomers rise up to around 10000. The library was used after 
minimization by OPLS-3 ff without further modifications.  
 
2.5. Virtual screening workflow 
Docking with XP scoring method within Glide has been adopted to dock the library into the acarbose 
defined enzymatic pocket with the default parameters, and the best ranked 3300 (30% of the molecules 
giving a scoring value of at least -8.0 kcal/mol) ranking poses of each molecule were retained for the 
next step of hits enrichment, by Prime/MM-GSBA (Bell et al., 2012). Finally, 20 ns molecular dynamic 
(MD) simulations were performed by using the docking poses of that compounds with the best free 
binding energy. The MD simulation trajectory analysis led us to identify the final hits for in vitro 
analysis. MD simulations allow to study the connections of the best ranked pose found by Glide and 
ranked by Prime, as well as to observe the time-dependent evolution of the interactions between ligand 
and enzyme, not detectable from the docking study only.  
2.6. Prime/MM-GBSA  
The top 30% of the poses obtained by docking od the entire library with Glide/XP scoring function 
were retained and submitted for MM/GBSA calculations performed with Prime module of Maestro. 
All the parameters were kept default. MM/GBSA is able to calculate the free binding energy of the 
complex ligand-enzyme in a water environment. The energy was estimated by the OPLS3 force field 
(Harder et al., 2016) for molecular mechanic energy (EMM) and the surface-generalized Born model 
(SGBM) for polar solvation energy (VSGB), and the apolar solvation factor (GSA). This energetic term 
is calculated for the complex, for the ligand and for the protein alone, then the binding free energy 
(ΔGbind) is finally obtained by the following equation: 
G = EMM + GSGB + GSA 
ΔGbind = Gcomplex – (Gprotein – Gligand)   
The top-12 compounds ranked by the free binding energy returned by MM/GBSA experiments were 
submitted for MD (Figure 3). 
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Figure 3. Superimposing of the four ligands (1-4) selected after MD simulations. 
 
2.7. Molecular Dynamics (MD) simulations 
The docked tripeptide-enzyme poses were subjected to MD simulations in water (Hospital, Goñi, 
Orozco and Gelpì, 2015). Desmond has been employed for the simulations. The complex was inserted 
in aqueous environment. The model constitutes of a box of water in which is inserted the complex. 
The box has a minimum size as to contain the complex ensuring a distance of 10 Å from the edge of 
the box and the protein. In order to neutralize the system, 0.15 M NaCl has been added to the system. 
The OPLS3 ff was used for all the experiments. TIP3P-TIP4P model (Penna and Lennart, 2001) was 
used water. The system was minimized up to 2000 steps, holding all the protein and ligand atoms. The 
minimized system was subjected to MD simulations, using the NPT ensemble and periodic boundary 
conditions for 20 ns. To control the pressure Martyna-Tobias-Klein method was used which allows to 
keep the pressure of the system at 1.01 bar by using the isotropic coupling method. The Nose-Hoover 
thermostat was applied to control the temperature at 310K. The trajectories and other parameters were 
saved every 20 and 1.2 ps respectively to returns 1000 frames. The simulation analysis was done by the 
simulation interactive diagram (SID), especially useful to visualize the RMSD fluctuations of ligand and 
enzyme, hydrogen bonds stability, rotation of groups on the ligand, van der Waals interactions over the 
simulation trajectories and overall stability of the secondary structure of the enzyme. 
2.8. MetaCore/MetaDrug Applications 
1. The hit molecules obtained from docking and MD simulations protocol were evaluated for the 
investigation of their therapeutic activity, pharmacokinetic and toxicity properties by using 
MetaCore/MetaDrug comprehensive systems biology analysis suite of Clarivate Analytics with the help 
of available ADME, disease and toxicity QSAR models (Mollica, Costante, Akdemirb et al., 2015). 
MetaCore is based on a high-quality, manually-curated database of molecular interactions, molecular 
pathways, gene-disease associations, chemical metabolism and toxicity information.  The hit molecules 
obtained from virtual screening were tested for their biological effects as potential AGI candidates. 
Furthermore, various toxic effects such as mutagenecity, anemia, carcinogenicity, cardiotoxicity, 
cytotoxicity, epididymis toxicity, genotoxicity, hepatotoxicity, kidney necrosis, kidney growth, liver 
 6 
choleastasis, etc. were predicted by 26 different toxicity QSAR models under MetaCore 
(https://portal.genego.com/).  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
COMPOUNDS SEQUENCE STRUCTURES Docking 
score 
(kcal/mol) 
G binding 
free energy 
(kcal/mol) 
MS calculated MS found 
          1 H-Phe-Arg-Asn-NH2 
N
H
H
N
NH 2
O
NH 2
O
O
H2N
O
NH
NH
NH 2
 
-9.363 -69.896 434.24 435.1 
          2 H-Trp-Arg-Ala-NH2 
N
H
H
N
NH2
CH3O
O
H2N
O
NH
NH
NH
NH2
 
-8.108 -72.861 430.24 431.3 
          3 H-Lys-Arg-Met-NH2 
N
H
H
N
NH2
O
S CH3
O
NH
NH
NH2
O
H2N
NH2
 
-9.569 -69.328 432.26 433.5 
          4 H-Asn-Arg-Asn-NH2 
N
H
H
N
NH2
O
NH2
O
O
H2N
O
NH2
O
NH
NH
NH2
 
-9.094 -79.613 401.21 402.4 
 
Table 1. Structures of compounds 1-4, docking scores, G free energy, MS data. 
 3. Chemistry 
3.1. Synthesis of compounds 
The synthesis of compounds 1–4 was performed by solid phase peptide synthesis (SPPS)(Mollica, 
Pinnen, Stefanucci and Costante, 2013; Mollica, Costante, Novellino et al., 2015) (Table 1). The N 
terminus protecting group was Fmoc, the protection group of the side chains of the amino acids were 
tert-butyloxy-carbonyl for Lysine and Tryptophan, Pbf for Arginine, Trityl for Asn. We used Rink 
amide resin with a 1.2 mMol/g loading, to obtain amidates peptides at the C terminus, the system 
TBTU/HOBt/DIPEA was used as coupling mixture and piperidine 20% in DMF for Fmoc group 
deprotection as previously reported by our group (Scheme 1). Purification via RP-HPLC afforded the 
desired peptides in excellent yields. Peptides were characterized by 1H NMR and Ms spectrometer. 
3.2. Materials and Methods 
Solvents and reagents were purchased from WVR (Italy) and used as supplied without further 
purification. Amino acids were purchased from GLS Shanghai (China). 1H NMR spectra were recorded 
at 25° C on a 300 MHz Varian Mercury spectrometer. Chemical shifts are reported in parts per million 
(δ) downfield from the internal standard TMS. Mass spectra were recorded on a LCQ Finnigan-Mat 
mass spectrometer (San Jose, CA) by ESI-spay source and ion trap analyzer. The capillary temperature 
was set at 200 °C and the spray voltage at 4.00 kV. The electropray was formed by using nitrogen (N2) 
as both the sheath gas and the auxiliary gas with a flow of elium. The purity of final TFA salts was 
confirmed by NMR analysis, ESI-LRMS, and analytical RP-HPLC recorded at 216, 235 254, and 275 
nm (Waters C18 4.6 mm × 150 mm) at a flow rate of 1 mL/min, using as eluent a gradient of 
H2O/acetonitrile−0.1% TFA ranging from 5% ACN to 90% ACN in 32 minutes, and was found to 
be≥96%. 
3.3. Synthesis  
3.3.1. Resin loading 
The Rink Amid Fmoc resin was deprotected by 20% piperidine in DMF (2 × 15 min). The resin was 
flush washed by treatment with MeOH/DMF/DCM repeated three times each. The first amino acid to 
load (3 equiv) is dissolved in a flask in DMF (5 mL), then TBTU (3 equiv) and DIPEA (6 equiv) were 
added and the resulting mixture was shaked for 10 minutes, then added to the resin. The coupling was 
kept shacked vigorously overnight. Kaiser test was routinely used to check the coupling. After 
competition, the resin was flush washed with MeOH/DMF/DCM three times each.  
3.3.2. Cleavage and purification 
In order to cleave the peptide from the resin, a mixture of TFA/H2O/TIPS 95:2.5:2.5 (8 mL for 1 h) 
was added to the plastic vessel and shacked for 2.5 hours. After this time the solution is collected, 
concentrated under vacuum and the resulting ˜1 mL of solution, that was precipitated in cold ether. 
The peptide was separated from the solution by centrifugation at 4000 rpm for 5 minutes, and the ether 
removed. This process war repeated four times, the obtained solid was then dried at reduced pressure. 
Final peptides 1-4 were purified by HPLC using a Waters XBridge semiprep C18, 5.0 μm, 250 mm× 10 
mm column at a flow rate of 4 mL/min on a Waters pump 600, using as eluent a linear gradient of 
H2O+0.1% TFA/ACN+0.1% TFA, from 5% ACN to 90% ACN in 32 min.  
 NH2
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Scheme 1. Preparation of products 1-4 via SPPS.  
 
4. Enzyme Assay 
4.1. α-glucosidase inhibition  
The four peptides 1-4 were tested for inhibition of α-glucosidase as previously reported by our research 
group (Zengin, 2016) (Table 2). Compound solution (50 µL) was mixed with GSH (50 µL), α-
glucosidase stock (from Saccharomyces cerevisiae, EC 3.2.1.20, Sigma) (50 µL) in buffer (phosphate, 
pH 6.8) and PNPG (4-N-trophenyl-α-D-glucopyranoside) (50 µL) in a 96-well microplate and 
incubated for 15 min at 37 °C. Similarly, a blank was prepared by adding compound solution to all 
reaction reagents without enzyme (α-glucosidase) solution. The reaction was then stopped with the 
addition of Na2CO3 (50 µL, 0.2 M). The sample and blank absorbances were read at 400 nm. The 
absorbance of the blank was subtracted from that of the sample inhibitory activity of each compounds 
on α-glucosidase activity was calculated as equivalents of acarbose. 
 
Peptides Metal chelating (mgEDTAE/g sample) Glucosidase Inhibition 
(molACAE/g sample) 
Compound 1 5,63±0.20 0,45±0.08 
Compound 2 5,58±0.43 0,70±0.09 
Compound 3 5,46±1.29 0,58±0.05 
Compound 4 3,86±0.18 0,36±0.08 
 
Table 2. Biological assay of compounds 1-4. 
  
5. Results and discussion 
VS on glucosidase has been proved to be a valuable tool to find new lead compounds (Sanders et al., 
2012). To discover novel inhibitor candidates of α-glucosidase, a virtual peptide library was generated in 
house and screened in silico. The virtual screening was carried out into three steps, firstly all the ligands 
were screened by docking performed by Glide/XP scoring function (Halgren et al., 2004). In a second 
step, around 30% of the ligands with high-docking score have been retained for MM/GBSA re-scoring. 
The top-10 hits were retained for MD simulations. After RMSD analysis, four peptides have been 
selected for synthesis by SPPS methodology and tested by in vitro analysis in order to validate the virtual 
screening results. In vitro analysis showed that compounds 1-4 inhibited α-glucosidase with an inhibitory 
potency calculated in equivalents of acarbose reported in Table 2. Compound 2 was found to be the 
most active among this series. Several papers deal with the developing of suitable computational 
methods of scoring accurately the molecules contained in virtual libraries generally composed of ‘small 
molecules’ (Sliwoski, Kothiwale, Meiler and Lowe, 2014); however, at the best of our knowledge this is 
the first attempt to use a combinatorial peptides’ library for a virtual screening.  We used Glide/XP to 
produce the docking poses, as it was found to be able to reproduce the pose of the crystallographic 
ligand acarbose, and the best 30% compounds were used for rescoring by MM/GBSA, which in several 
papers is reported to be one of the most reliable method of rescoring the hits after docking. 
Prime/MM-GBSA has been applied taking in consideration its good performance to rank the potential 
ligands better than Glide. This quality has been validated in several targets, which is probably due to its 
realistic parametrization of the solvation that occurs to the complex in water. The satisfactory 
combination of Glide to generate reliable binding poses joined to accuracy of Prime in the calculation 
of the free binding energy produced 12 best hits, that were reduced to four after MD simulations. As 
illustrated in Figure 4, the four inhibitor candidates have similar predicted docking poses in the binding 
to -glucosidase (Figure 1A), and their highly flexible structures, fit well into the acarbose-binding 
pocket, due to a similarity in steric and electronic distribution. The potency of the novel AGIs was in 
micro-molar range, however none of the compounds reached the docking score and MM/GBSA 
calculated for acarbose, in agreement with the activity observed for the four peptides (the most active 
peptide (2) has an activity equal to 0.7 equivalents of acarbose).  
 
 
  
 
 
  
Figure 4. Docking poses of compounds 1-4 into the binding pocket of α-glucosidase. 
 
The crystallographic ligand acarbose interacts with α-glucosidase in the enzymatic cavity by establishing 
several hydrogen-bond (H-bond) interactions. In particular, the key interactions involve: Asp1157, 
Asp1279, Lys1460, Arg1510, Asp1526, His1584. The peptide inhibitors contain several hydrophilic 
groups, such as the amide and amine groups, which may mimicry the polar interactions with the polar 
region of the binding site in a similar way of acarbose. However, not all H-bond interactions made by 
acarbose are respected, such as for the H-bond toward Arg1510, His1584 that were not observed for 
compounds 2 and 3. All the tested peptides (compounds 1-4) share the following interactions: 
Asp1157, Asp1279, Asp1526. Peptide 4 has also in common with acarbose the H-bond to Lys1460, 
whereas the compounds 1 and 2 do not display this H bond but interact to the same residue by 
establishing a π-cation interaction. Peptide 3 does not interact with Lys1460 residue but forms a π-
cation interaction with Phe1559. Moreover, all the selected compounds have further interaction to 
Tyr1251 (π -cation), Asp1420 (ionic for 2 and 3 and H-bond for 1 and 4), Thr1586 (H-bond). Peptide 2 
which has shown the best activity, may provide a starting lead structure for further optimizations as 
selective inhibitor. The observed preferential inhibition of the compound 2 also provides helpful 
information about the preferential binding mode and key interactions. The best pose found for 2 
indeed showed the presence of a folded motif, namely a -turn inverse turn (Guruprasad and Rajkumar, 
2000; Mollica et al., 2006; Aschi et al., 2003; Morera et al., 2005; Durdagi et al., 2013), centered at the 
lysine residues and stabilized by the intramolecular H-bond formed with the interaction of the carbonyl 
oxygen of the Trp residue (i) and the proton of the amide group of the alanine residue (i+2) Figure 5. 
 
  
Figure 5. Peptide 2, intramolecular H bond stabilizes a ß-turn structure. 
 
MetaCore/MetaDrug Applications 
When Tables 3-5 are examined it can be seen that selected peptides can have some therapeutic 
potentials (cut-off value for therapeutic potential is 0.5). The values in brackets in this table is Tanimato 
Prioritization (TP). A maximal Tanimato coefficient calculated for all molecules in a training set of a 
QSAR model indicates similarity of the analyzed structure to the most similar compound in the training 
set. The high docking scores and the acceptability of the values of therapeutic activities alone may not 
be enough for the molecules we choose. Taking this into account we have investigated the ADME 
properties like BBB (blood brain barrier), G-log P (lipophilicity), Prot-bind, % (connectivity to blood 
serum proteins) and Prot-bind, log t (connectivity to blood serum albumin proteins). These parameters 
are very important for the candidate drug-like molecules (Table 3). ADME/QSAR models, therapeutic 
and toxicity prediction profiles of 4 peptides with positive control molecules are compared. Based on 
results, lipophilicity (log of compound octanol/water distribution) values of designed peptides are 
found high (Table 4, Table 5). Although blood brain barrier penetration of 4 peptides are smaller than 
cutoff value (-0.3), their values are similar/smaller than positive controls. Within the 4 peptides, 
peptides 1, 2 and 3 showed potential antidiabetic activities (Table 4). 
 
ADME QSAR Models 
 Peptide-1 Peptide-2 Peptide-3 Peptide-4 Acarbose Voglibose Miglitol 
BBB, log ratio (1) -0.88 (38.92) -0.81 (59.20) -1.02 (45.16) -0.84 (43.10) -0.93 (44.70) -1.00 (32.69) -1.24 (36.91) 
G-LogP (2) 0.79 1.55 1.04 0.33 0.68 -1.01 -1.44 
Prot-bind, % (3) 40.96 (58.50) 51.38 (47.34) 37.02 (45.16) 37.02 (45.45) 52.66 (58.33) 21.48 (41.33) 20.23 (44.44) 
Prot-bind, Log t (4) -0.13 (38.92) 0.05 (59.20) -0.14 (45.16) -0.33 (43.10) -0.47 (44.70) -0.43 (32.69) -0.38 (36.91) 
WSol, log mg/L (5) 1.65 1.97 2.27 2.28 3.31 4.17 5.08 
Table 3. ADME QSAR Models.  
1. Blood brain barrier penetration model. The data is expressed as log values of the ratio of the metabolite concentrations in brain and plasma. Cutoff is -0.3. Larger 
values indicate that the metabolite is more likely to enter the brain. Model description: N=107, R2=0.89, RMSE=0.26.  
2. Lipophilicity, log of compound octanol-water distribution. Cutoffs are -0.4 to 5.6. Values greater than 5.6 correspond to overly hydrophobic compounds. Model 
description: N=13474, R2=0.95, RMSE=0.21. 
3. Human serum protein binding, %. Cutoff is 50%. A value of more than 95% is highly bound, less than 50% is a low binding metabolite. Model description: 
N=265, R2=0.909, RMSE=10.11.  
4. Affinity to human serum albumin, log value of the retention time. Cutoff is 0. Positive values correspond to higher protein binding, negative values to lower 
protein binding. An acceptable level of binding is project dependent. The model is based on retention times of compounds assayed by HPLC using an immobilized 
HSA column. Values are expressed as log values of the retention time. Model description: N=95, R2=0.904, RMSE=0.2.  
5. Water solubility at 25oC, log mg/L. Cutoffs are from 2 to 4. An acceptable level of solubility is project dependent. Model description: N=2871, 2=0.91, 
RMSE=0.54. 
 
 
 
 
 
 Prediction of Therapeutic Activity 
 Peptide-1 Peptide-2 Peptide-3 Peptide-4 Acarbose Voglibose Miglitol 
Allergy (1) 0.17 (65.54) 0.17 (51.80) 0.33 (43.16) 0.33 (54.46) 0.30 (52.23) 0.42 (42.86) 0.44 (38.13) 
Alzheimer (2) 0.58 (71.23) 0.45 (79.21) 0.47 (48.82) 0.65 (58.82) 0.43 (42.98) 0.67 (48.19) 0.54 (50.00) 
Angina (3) 0.28 (54.50) 0.32 (69.86) 0.32 (57.72) 0.30 (69.81) 0.08 (60.54) 0.29 (46.15) 0.47 (41.18) 
Arthritis (4) 0.85 (60.10) 0.96 (76.09) 0.82 (44.72) 0.71 (50.00) 0.74 (34.25) 0.46 (46.15) 0.33 (42.11) 
Asthma (5) 0.64 (67.35) 0.60 (76.09) 0.51 (57.72) 0.45 (69.81) 0.50 (48.11) 0.64 (48.19) 0.66 (50.00) 
Bacterial (6) 0.22 67.35) 0.24 (67.51) 0.72 (50.53) 0.74 (59.26) 0.67 (63.01) 0.81 (44.80) 0.84 (45.90) 
Cancer (7) 0.76 (55.28) 0.76 (67.59) 0.86 (57.72) 0.79 (69.81) 0.17 (100.00) 0.84 (71.62) 0.90 (90.77) 
Depression (8) 0.45 (66.42) 0.54 (81.01) 0.52 (47.20) 0.47 (57.41) 0.07 (51.93) 0.16 (61.90) 0.16 (65.00) 
Diabetes (9) 0.56 (71.64) 0.42 (79.35) 0.57 (42.62) 0.55 (48.15) 0.34 (100.00) 0.63(100.00) 0.46 (78.26) 
HIV(10) 0.81 (68.03) 0.74 (76.09) 0.69 (47.20) 0.65 (57.41) 0.46 (58.33) 0.76 (48.19) 0.67 (50.00) 
Heart Failure (11) 0.95 (66.92) 0.90 (82.90) 0.84 (45.16) 0.84 (45.76) 0.65 (50.21) 0.34 (41.27) 0.36 (40.98) 
Hyperlipidemia (12) 0.46 (51.72) 0.55 (42.01) 0.47 (37.67) 0.48 (37.50) 0.58 (55.75) 0.38 (43.48) 0.34 (43.06) 
Hypertension (13) 0.76 (63.41) 0.53 (65.05) 0.54 (49.01) 0.63 (59.29) 0.36 (60.54) 0.53 (77.14) 0.68 (98.36) 
Inflammation (14) 0.36 (51.72) 0.22 (61.83) 0.41 (50.39) 0.47 (57.89) 0.16 (100.00) 0.37 (44.76) 0.20 (50.51) 
Migraine (15) 0.66 (68.03) 0.60 (76.09) 0.73 (57.72) 0.65 (69.81) 0.52 (58.33) 0.69 (51.25) 0.63 (55.26) 
Mycosis (16) 0.38 (71.64) 0.26 (65.05) 0.34 (44.68) 0.39 (44.44) 0.30 (56.28) 0.39 (40.94) 0.49 (36.18) 
Obesity (17) 0.91 (60.10) 0.97 (76.09) 0.68 (41.73) 0.55 (50.00) 0.85 (48.11) 0.28 (46.02) 0.05 (42.11) 
Osteoporosis (18) 0.88 (60.10) 0.87 (76.09) 0.27 (49.33) 0.28 (51.00) 0.48 (48.11) 0.47 (46.02) 0.64 (42.11) 
Pain (19) 0.37 (56.69) 0.35 (82.90) 0.37 (50.85) 0.45 (62.38) 0.04 (60.54) 0.50 (42.70) 0.67 (41.35) 
Parkinson (20) 0.53 (67.35) 0.43 (81.01) 0.38 (38.51) 0.47 (43.54) 0.30 (52.23) 0.60 (38.46) 0.48 (35.00) 
Psoriasis (21) 0.42 (65.54) 0.29 (67.51) 0.28 (49.01) 0.29 (45.76) 0.33 (46.64) 0.26 (39.20) 0.27 (35.71) 
Schizophrenia (22) 0.44 (48.05) 0.38 (65.05) 0.30 (52.99) 0.29 (63.37) 0.35 (56.04) 0.32 (39.20) 0.30 (36.89) 
Skin Diseases (23) 0.49 (56.04) 0.35 (47.09) 0.54 (45.30) 0.59 (39.19) 0.35 (56.04) 0.75 (36.94) 0.58 (43.06) 
Thrombosis (24) 0.65 (56.25) 0.47 (65.05) 0.47 (53.15) 0.58 (60.82) 0.29 (58.33) 0.24 (40.86) 0.19 (38.89) 
Viral (25) 0.48 (71.64) 0.68 (56.57) 0.42 (48.82) 0.51 (47.24) 0.28 (50.23) 0.53 (40.86) 0.57 (48.44) 
Table 4. Prediction of therapeutic activities. 
1. Potential antiallergic activity. Cutoff is 0.5. Values higher than 0.5 indicate potentially active compounds. Training set consists of approved drugs. Model 
description: Training set N=258, Test set N=47, Sensitivity= 0.87, Specificity=0.88, Accuracy=0.87, MCC=0.74.  
2. Potential activity against Alzheimer's disease. Cutoff is 0.5. Values higher than 0.5 indicate potentially active compounds. Training set consists of approved drugs, 
drug candidates in clinical trials and preclinical compounds with in vivo activity. Model description: Training set N=261, Test set N=44, Sensitivity= 0.91, 
Specificity=0.82, Accuracy=0.86, MCC=0.73.  
3. Potential antianginal activity. Cutoff is 0.5. Values higher than 0.5 indicate potentially active compounds. Training set consists of approved drugs, drug candidates 
in clinical trials and preclinical compounds with in vivo activity. Model description: Training set N=546, Test set N=95, Sensitivity= 0.90, Specificity=0.93, 
Accuracy=0.92, MCC=0.83.  
4. Potential activity against arthritis. Cutoff is 0.5. Values higher than 0.5 indicate potentially active compounds. Training set consists of approved drugs, drug 
candidates in clinical trials and preclinical compounds with in vivo activity. Model description: Training set N=460, Test set N=77, Sensitivity= 0.98, Specificity=0.94, 
Accuracy=0.96, MCC=0.92. 
5. Potential activity against asthma. Cutoff is 0.5. Values higher than 0.5 indicate potentially active compounds. Training set consists of approved drugs, drug 
candidates in clinical trials and preclinical compounds with in vivo activity. Model description: Training set N=366, Test set N=63, Sensitivity= 0.92, Specificity=0.86, 
Accuracy=0.89, MCC=0.78. 
6. Potential antibacterial activity. Cutoff is 0.5. Values higher than 0.5 indicate potentially active compounds. Training set consists of approved drugs. Model 
description: Training set N=530, Test set N=97, Sensitivity= 0.87, Specificity=0.90, Accuracy=0.89, MCC=0.77. 
7. Potential activity against cancer. Cutoff is 0.5. Values higher than 0.5 indicate potentially active compounds. Training set consists of approved drugs. Model 
description: Training set N=886, Test set N=167, Sensitivity= 0.89, Specificity=0.83, Accuracy=0.86, MCC=0.72. 
8. Potential activity against depression. Cutoff is 0.5. Values higher than 0.5 indicate potentially active compounds. Training set consists of approved drugs. Model 
description: Training set N=335, Test set N=62, Sensitivity= 0.93, Specificity=0.82, Accuracy=0.87, MCC=0.75. 
9. Potential antidiabetic activity. Cutoff is 0.5. Values higher than 0.5 indicate potentially active compounds. Training set consists of approved drugs, drug candidates 
in clinical trials and preclinical compounds with in vivo activity. Model description: Training set N=195, Test set N=34, Sensitivity= 0.85, Specificity=0.93, 
Accuracy=0.88, MCC=0.77. 
10. Potential activity against HIV. Cutoff is 0.5. Values higher than 0.5 indicate potentially active compounds. Training set consists of approved drugs, drug 
candidates in clinical trials and preclinical compounds with in vivo activity. Model description: Training set N=491, Test set N=80, Sensitivity= 0.80, Specificity=0.86, 
Accuracy=0.84, MCC=0.67. 
11. Potential activity against heart failure. Cutoff is 0.5. Values higher than 0.5 indicate potentially active compounds. Training set consists of approved drugs. Model 
description: Training set N=204, Test set N=33, Sensitivity= 0.78, Specificity=0.87, Accuracy=0.82, MCC=0.64. 
12. Potential antihyperlipidemic activity. Cutoff is 0.5. Values higher than 0.5 indicate potentially active compounds. Training set consists of approved drugs. Model 
description: Training set N=185, Test set N=24, Sensitivity= 0.75, Specificity=0.92, Accuracy=0.83, MCC=0.68. 
13.  Potential antihypertensive activity. Cutoff is 0.5. Values higher than 0.5 indicate potentially active compounds. Training set consists of approved drugs. Model 
description: Training set N=554, Test set N=111, Sensitivity= 0.89, Specificity=0.81, Accuracy=0.85, MCC=0.70. 
14. Potential anti-inflammatory activity. Cutoff is 0.5. Values higher than 0.5 indicate potentially active compounds. Training set consists of approved drugs. Model 
description: Training set N=598, Test set N=93, Sensitivity= 0.86, Specificity=0.84, Accuracy=0.85, MCC=0.69. 
15. Potential activity against migraine. Cutoff is 0.5. Values higher than 0.5 indicate potentially active compounds. Training set consists of approved drugs, drug 
candidates in clinical trials and preclinical compounds with in vivo activity. Model description: Training set N=515, Test set N=98, Sensitivity= 0.81, Specificity=0.84, 
Accuracy=0.83, MCC=0.65. 
16. Potential antifungal activity. Cutoff is 0.5. Values higher than 0.5 indicate potentially active compounds. Training set consists of approved drugs. Model 
description: Training set N=172, Test set N=47, Sensitivity= 0.90, Specificity=0.88, Accuracy=0.89, MCC=0.79. 
17. Potential activity against obesity. Cutoff is 0.5. Values higher than 0.5 indicate potentially active compounds. Training set consists of approved drugs, drug 
candidates in clinical trials and preclinical compounds with in vivo activity. Model description: Training set N=472, Test set N=75, Sensitivity= 0.89, Specificity=0.97, 
Accuracy=0.93, MCC=0.87. 
 18. Potential anti-osteoporosis activity. Cutoff is 0.5. Values higher than 0.5 indicate potentially active compounds. Training set consists of approved drugs, drug 
candidates in clinical trials and preclinical compounds with in vivo activity. Model description: Training set N=595, Test set N=86, Sensitivity= 0.84, Specificity=0.85, 
Accuracy=0.85, MCC=0.70. 
19. Potential analgetic activity. Cutoff is 0.5. Values higher than 0.5 indicate potentially active compounds. Training set consists of approved drugs. Model description: 
Training set N=525, Test set N=84, Sensitivity= 0.92, Specificity=0.67, Accuracy=0.79, MCC=0.60. 
20. Potential activity against Parkinson's disease. Cutoff is 0.5. Values higher than 0.5 indicate potentially active compounds. Training set consists of approved drugs, 
drug candidates in clinical trials and preclinical compounds with in vivo activity. Model description: Training set N=298, Test set N=49, Sensitivity= 0.96, 
Specificity=0.96, Accuracy=0.96, MCC=0.92. 
21. Potential activity against psoriasis. Cutoff is 0.5. Values higher than 0.5 indicate potentially active compounds. Training set consists of approved drugs, drug 
candidates in clinical trials and preclinical compounds with in vivo activity. Model description: Training set N=199, Test set N=32, Sensitivity= 0.93, Specificity=0.82, 
Accuracy=0.89, MCC=0.74. 
22. Potential activity against schizophrenia. Cutoff is 0.5. Values higher than 0.5 indicate potentially active compounds. Training set consists of approved drugs, drug 
candidates in clinical trials and preclinical compounds with in vivo activity. Model description: Training set N=616, Test set N=93, Sensitivity= 0.89, Specificity=0.91, 
Accuracy=0.90, MCC=0.80. 
23. Potential activity against skin diseases. Cutoff is 0.5. Values higher than 0.5 indicate potentially active compounds. Training set consists of approved drugs. Model 
description: Training set N=255, Test set N=36, Sensitivity= 1.00, Specificity=0.76, Accuracy=0.86, MCC=0.76. 
24. Potential antithrombotic activity. Cutoff is 0.5. Values higher than 0.5 indicate potentially active compounds. Training set consists of approved drugs, drug 
candidates in clinical trials and preclinical compounds with in vivo activity. Model description: Training set N=453, Test set N=80, Sensitivity= 0.98, Specificity=0.95, 
Accuracy=0.97, MCC=0.93. 
25. Potential antiviral activity. Cutoff is 0.5. Values higher than 0.5 indicate potentially active compounds. Training set consists of approved drugs. Model description: 
Training set N=206, Test set N=35, Sensitivity= 0.92, Specificity=0.95, Accuracy=0.94, MCC=0.88. 
  
 
Prediction of Toxic Effects 
 Peptide-1 Peptide-2 Peptide-3 Peptide-4 Acarbose Voglibose Miglitole 
AMES (1) 0.64 (54.14) 0.50 (43.10) 0.52 (41.18) 0.50 (47.73) 0.55 (50.62) 0.43 (41.27) 0.32 (44.26) 
Anemia (2) 0.35 (49.65) 0.28 (46.08) 0.32 (45.16) 0.36 (45.45) 0.09 (56.73) 0.56 (39.20) 0.42 (44.44) 
Carcinogenicity (3) 0.16 (71.64) 0.08 (82.90) 0.37 (69.61) 0.46 (82.76) 0.16 (54.47) 0.90 (60.56) 0.95 (63.24) 
Carcinogenicity 
Mouse Female (4) 
0.12 (71.64) 0.11 (82.90) 0.31 (46.92) 0.30 (63.89) 
0.20 (54.47) 0.72 (60.56) 0.75 (63.24) 
Carcinogenicity 
Mouse Male (5) 
0.28 (71.64) 0.15 (82.90) 0.40 (69.61) 0.31 (82.76) 
0.17 (54.47) 0.69 (60.56) 0.56 (63.24) 
Carcinogenicity Rat 
Female (6) 
0.04 (71.64) 0.03 (82.90) 0.17 (50.00) 0.25 (63.89) 
0.09 (54.47) 0.79 (43.33) 0.81 (42.67) 
Carcinogenicity Rat 
Male (7) 
0.06 (71.64) 0.06 (82.90) 0.35 (50.00) 0.37 (58.95) 
0.17 (54.47) 0.89 (41.74) 0.86 (40.51) 
Cardiotoxicity (8) 0.20 (39.16) 0.11 (46.08) 0.15 (40.14) 0.25 (45.45) 0.86 (48.42) 0.81 (39.20) 0.90 (36.91) 
Cytotoxicity Model, -
log GI50 (M) (9) 
4.82 (52.98) 5.12 (58.75) 4.42 (48.36) 4.78 (59.05) 
5.01 (55.94) 5.28 (48.82) 4.55 (46.46) 
Epididymis Toxicity 
(10) 
0.20 (51.70) 0.24 (65.05) 0.34 (41.12) 0.34 (50.55) 
0.38 (44.88) 0.62 (37.80) 0.67 (43.06) 
Genotoxicity (11) 0.33 (65.54) 0.37 (82.90) 0.46 (49.33) 0.54 (47.73)  0.31 (54.47) 0.92 (41.33) 0.75 (38.41) 
Hepatotoxicity (12) 0.17 (69.62) 0.14 (92.49) 0.26 (53.23) 0.28 (60.00) 0.59 (54.68) 0.56 (100.00) 0.48 (78.26) 
Kidney Necrosis (13) 0.15 (47.14) 0.06 (55.36) 0.34 (40.14) 0.55 (45.45) 0.17 (55.75) 0.87 (41.74) 0.63 (38.84) 
Kidney Weight Gain 
(14) 0.10 (60.56) 
0.09 (92.49) 0.36 (50.00) 0.32 (58.95) 
0.42 (58.33) 0.85 (69.57) 0.52 (62.86) 
Liver Cholestasis (15) 0.24 (58.50) 0.15 (55.36) 0.15 (45.16) 0.29 (45.45) 0.43 (49.05) 0.63 (100.00) 0.66 (78.26) 
Liver Lipid 
Accumulation (16) 0.28 (60.56) 
0.24 (92.49) 0.26 (40.31) 0.29 (47.24) 
0.37 (48.80) 0.46 (48.19) 0.60 (42.86) 
Liver Necrosis (17) 0.49 (40.91) 0.21 (54.65) 0.50 (41.78) 0.38 (38.06) 0.32 (50.62) 0.83 (41.75) 0.81 (41.58) 
Liver Weight Gain (18) 0.41 (48.17) 0.05 (59.26) 0.54 (36.50) 0.47 (37.30) 0.40 (54.10) 0.95 (100.00) 0.74 (78.26) 
MRTD (19) 0.37 (51.55) 0.26 (58.22) 0.69 (53.23) 0.64 (60.00) 0.98 (59.57) 1.14 (78.26) 1.31 (100.00) 
Nasal Pathology (20) 0.07 (51.18) 0.09 (48.88) 0.21 (39.31) 0.11 (46.88) 0.20 (35.08) 0.39 (34.21) 0.70 (35.62) 
Nephron Injury (21) 0.29 (53.85) 0.02 (55.22) 0.32 (49.33) 0.47 (47.24) 0.19 (58.33) 0.77 (48.19) 0.77 (44.44) 
Nephrotoxicity (22) 0.10 (53.85) 0.13 (55.22) 0.35 (49.33) 0.40 (59.81) 0.36 (58.33) 0.57 (100.00) 0.66 (100.00) 
Neurotoxicity (23) 0.26 (48.28) 0.12 (67.86) 0.41 (36.36) 0.35 (38.78) 0.25 (47.78) 0.86 (44.25) 0.86 (44.44) 
Pulmonary Toxicity 
(24) 0.06 (71.64) 
0.05 (67.59) 0.11 (43.69) 0.12 (54.02) 
0.22 (61.71) 0.29 (51.25) 0.56 (55.26) 
SkinSens, EC3 (25) 
28.63 
(31.62) 
43.94 (51.06) 
27.88 
(37.89) 
13.69 
(44.44) 
49.35 (24.11) 4.19 (33.33) 4.73 (28.00) 
Testicular Toxicity (26) 0.46 (51.70) 0.59 (65.05) 0.43 (45.45) 0.36 (50.55) 0.22 (54.10) 0.42 (52.38) 0.49 (55.00) 
Table 5. Prediction of toxicity values. 
1. Potential to be mutagenic (AMES positive), range from 0 to 1. A value of 1 is AMES positive (mutagenic), and a value of 0 is AMES negative (non-mutagenic). 
Cutoff is 0.5. Values close to zero are preferable. The AMES assay is based upon the reversion of mutations in the histidine operon in the bacterium Salmonella 
enterica sv Typhimurium. 
2. Potential for causing anemia. Cutoff is 0.5. Values higher than 0.5 indicate potentially toxic compounds. Training set consists of chemicals and drugs causing 
anemia in vivo. Model organisms: human. Model description: Training set N=324, Test set N=51, Sensitivity= 0.82, Specificity=0.90, Accuracy=0.86, MCC=0.72. 
 3. Potential for inducing carcinogenicity in rats and mice. Cutoff is 0.5. Values higher than 0.5 indicate potentially toxic compounds. Training set consists of chemicals 
and drugs causing carcinogenicity in vivo. Model organisms: mouse, rat. Model description: Training set N=1210, Test set N=185, Sensitivity= 0.96, Specificity=0.90, 
Accuracy=0.93, MCC=0.86. 
4. Potential for inducing carcinogenicity in female mice. Cutoff is 0.5. Values higher than 0.5 indicate potentially toxic compounds. Training set consists of chemicals 
and drugs causing carcinogenicity in vivo. Model organisms: female mice. Model description: Training set N=640, Test set N=94, Sensitivity= 0.90, Specificity=0.93, 
Accuracy=0.92, MCC=0.83. 
5. Potential for inducing carcinogenicity in male mice. Cutoff is 0.5. Values higher than 0.5 indicate potentially toxic compounds. Training set consists of chemicals 
and drugs causing carcinogenicity in vivo. Model organisms: mouse male. Model description: Training set N=584, Test set N=93, Sensitivity= 0.91, Specificity=0.88, 
Accuracy=0.89, MCC=0.78. 
6. Potential for inducing carcinogenicity in female rats. Cutoff is 0.5. Values higher than 0.5 indicate potentially toxic compounds. Training set consists of chemicals 
and drugs causing carcinogenicity in vivo. Model organisms: female rat. Model description: Training set N=667, Test set N=120, Sensitivity= 0.90, Specificity=0.96, 
Accuracy=0.93, MCC=0.86. 
7. Potential for inducing carcinogenicity in male rats. Cutoff is 0.5. Values higher than 0.5 indicate potentially toxic compounds. Training set consists of chemicals and 
drugs causing carcinogenicity in vivo. Model organisms: male rat. Model description: Training set N=715, Test set N=117, Sensitivity= 0.92, Specificity=0.88, 
Accuracy=0.90, MCC=0.79. 
8.  Potential for inducing cardiotoxicity. Cutoff is 0.5. Values higher than 0.5 indicate potentially toxic compounds. Training set consists of chemicals and drugs 
causing cardiotoxicity in vivo. Model organisms: mouse, rat, human. Model description: Training set N=143, Test set N=30, Sensitivity= 0.80, Specificity=1.00, 
Accuracy=0.90, MCC=0.82. 
9. Growth inhibition of MCF7 cell line (human caucasian breast adenocarcinoma), pGI50. Cutoff is 6. Values from 6 to 8 correspond to a toxic metabolite, values 
less than 6 are preferable, values less than 3 are more preferable and less toxic. Model description: N=1474, R2=0.9, RMSE=0.05. 
10. Potential for inducing epididymis toxicity. Training set consists of chemicals and drugs causing epididymis toxicity in vivo. Model organisms: mouse, rat, human. 
Cutoff is 0.5. Values higher than 0.5 indicate potentially toxic compounds. Model description: Training set N=252, Test set N=42, Sensitivity= 0.90, Specificity=0.86, 
Accuracy=0.88, MCC=0.76. 
11. Potential for inducing genotoxicity. Cutoff is 0.5. Values higher than 0.5 indicate potentially toxic compounds. Training set consists of chemicals and drugs 
causing genotoxicity in vivo. Model organisms: mouse, rat. Model description: Training set N=372, Test set N=86, Sensitivity= 0.75, Specificity=0.84, 
Accuracy=0.79, MCC=0.59. 
12. Potential for inducing hepatotoxicity. Cutoff is 0.5. Values higher than 0.5 indicate potentially toxic compounds. Training set consists of chemicals and drugs 
causing hepatotoxicity in vivo. Model organisms: mouse, rat, human. Model description: Training set N=1380, Test set N=231, Sensitivity= 0.73, Specificity=0.88, 
Accuracy=0.81, MCC=0.62. 
13. Potential for inducing kidney necrosis. Cutoff is 0.5. Values higher than 0.5 indicate potentially toxic compounds. Training set consists of chemicals and drugs 
causing renal necrosis in vivo. Model organisms: mouse, rat, human. Model description: Training set N=221, Test set N=42, Sensitivity= 0.96, Specificity=1.00, 
Accuracy=0.98, MCC=0.95. 
14. Potential for inducing kidney weight gain. Cutoff is 0.5. The values higher than 0.5 indicate potentially toxic compounds. Training set consists of chemicals and 
drugs causing kidney weight gain in vivo. Model organisms: mouse, rat. Model description: Training set N=240, Test set N=49, Sensitivity= 0.95, Specificity=1.00, 
Accuracy=0.98, MCC=0.96. 
15. Potential for inducing liver cholestasis. Cutoff is 0.5. Values higher than 0.5 indicate potentially toxic compounds. Training set consists of chemicals and drugs 
causing cholestasis in vivo. Model organisms: mouse, rat, human. Model description: Training set N=218, Test set N=35, Sensitivity= 0.79, Specificity=0.67, 
Accuracy=0.74, MCC=0.46. 
16. Potential for inducing liver lipid accumulation. Cutoff is 0.5. Values higher than 0.5 indicate potentially toxic compounds. Training set consists of chemicals and 
drugs causing lipid accumulation in vivo. Model organisms: mouse, rat, human. Model description: Training set N=172, Test set N=28, Sensitivity= 0.80, 
Specificity=0.85, Accuracy=0.82, MCC=0.64. 
17. Potential for inducing liver necrosis. Cutoff is 0.5. Values higher than 0.5 indicate potentially toxic compounds. Training set consists of chemicals and drugs 
causing hepatic necrosis in vivo. Model organisms: mouse, rat, human. Model description: Training set N=300, Test set N=57, Sensitivity= 0.91, Specificity=0.91, 
Accuracy=0.91, MCC=0.82. 
18. Potential for inducing liver weight gain. Cutoff is 0.5. Values higher than 0.5 indicate potential liver weight-changing compounds. Training set consists of 
chemicals and drugs causing liver weight gain in vivo. Model organisms: mouse, rat. Model description: Training set N=292, Test set N=52, Sensitivity= 1.00, 
Specificity=1.00, Accuracy=1.00, MCC=1.00. 
19. Maximum Recommended Therapeutic Dose, log mg/kg-bm/day, range is from -5 to 3. Cutoff is 0.5. Chemicals with high log MRTDs can be classified as mildly 
toxic compounds, chemicals with low log MRTDs as highly toxic compounds. Model description: N=1209, R2= 0.86, RMSE=0.42. 
20. Potential for causing nasal pathology. Training set consists of chemicals and drugs causing nasal pathology in vivo. Model organisms: mouse, rat, human. Cutoff is 
0.5. Values higher than 0.5 indicate potentially toxic compounds. Model description: Training set N=246, Test set N=47, Sensitivity= 1.00, Specificity=0.93, 
Accuracy=0.96, MCC=0.92. 
21. Potential for inducing nephron injury. Cutoff is 0.5. Values higher than 0.5 indicate potentially toxic compounds. Training set consists of chemicals and drugs 
causing nephron injury in vivo. Model organisms: mouse, rat, human. Model description: Training set N=598, Test set N=109, Sensitivity= 0.91, Specificity=1.00, 
Accuracy=0.96, MCC=0.93. 
22. Potential for inducing nephrotoxicity. Cutoff is 0.5. Values higher than 0.5 indicate potentially toxic compounds. Training set consists of chemicals and drugs 
causing nephrotoxicity in vivo. Model organisms: mouse, rat, human. Model description: Training set N=847, Test set N=154, Sensitivity= 0.90, Specificity=0.84, 
Accuracy=0.87, MCC=0.74. 
23. Potential for inducing neurotoxicity. Training set consists of chemicals and drugs causing neurotoxicity in vivo. Model organisms: mouse, rat, human. Cutoff is 
0.5. Values higher than 0.5 indicate potentially toxic compounds. Model description: Training set N=175, Test set N=34, Sensitivity= 0.94, Specificity=0.94, 
Accuracy=0.94, MCC=0.88. 
24. Potential for inducing pulmonary toxicity. Training set consists of chemicals and drugs causing pulmonary toxicity in vivo. Model organisms: mouse, rat, human. 
Cutoff is 0.5. Values higher than 0.5 indicate potentially toxic compounds. Model description: Training set N=482, Test set N=87, Sensitivity= 0.89, Specificity=0.88, 
Accuracy=0.89, MCC=0.77. 
25. Skin sensitization potential expressed as effective concentration 3, EC3 %. Values higher than 10 indicate weak and moderate sensitizers. Model description: 
N=89, R2=0.67, RMSE=22.56. 
26. t consists of chemicals and drugs causing testicular toxicity in vivo. Model organisms: mouse, rat, human. Cutoff is 0.5. Values higher than 0.5 indicate potentially 
toxic compounds. Model description: Training set N=439, Test set N=88, Sensitivity= 0.81, Specificity=0.85, Accuracy=0.83, MCC=0.66. 
 
6. CONCLUSION 
In summary, four potential α-glucosidase tripeptides inhibitors have been found by applying a 
hierarchic approach of virtual screening (Aschi et al., 2003). The novel peptides discovered, if 
compared with acarbose, possess a completely novel scaffold and showed distinct interaction modes in 
the acarbose-catalytic cavity to some extent. Results of binary QSAR models showed that synthesized 
peptides have similar/better pharmacokinetic and phramacodynamic properties compared to tested 
three known α-glucosidase inhibitors. Their importance is of great interest since the α-glucosidase 
 activity could be certainly mudulated by the plethora of peptide fragments present in the GI tract 
during the digestion of proteins. The distinct conformations of the most active peptide could help to 
enhance our knowledge, furnishing further models useful for the design of new α-glucosidase 
inhibitors. Also, taking in consideration that small peptides are naturally occurring substances, present 
in the GI tract in huge amount during digestion of native proteins, we consider that the leads found 
during this study may open the way to a new paradigm in the study of -glucosidase modulation, 
including dietary peptides and proteins, may concur to develop new tools to fight against type 2 
diabetes. 
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